Lantern Pharma Inc.
corporate_fare Company Profile
Lantern Pharma Inc. (NASDAQ:LTRN) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 31 items for LTRN at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-18, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 10/10, with 10 rated 8 or above. Recent SEC coverage for LTRN spans 8-K, 10-Q, PRE 14A, 424B5.
Recent high-impact activity:
- Lantern Pharma Q3: $7.6M Cash, Going-Concern Warning, Interim CEO After Sharma Exit
- Lantern Pharma Q3: $7.6M Cash, Going-Concern Doubt, $2M Settlement Accrual
- Lantern Pharma 10-Q: Second Nasdaq Deficiency, CEO Exit and $2M Settlement Accrual
- Lantern Pharma Seeks Approval to Double Authorized Shares and Issue 3.67M Warrant Shares
- Taiwan Approvals Open Next Stage of HARMONIC Trial for LP-300 in EGFR-Mutant NSCLC
Financial Snapshot
Short Interest & Short Volume
2.68 days to coverFINRA reported short interest of 924,479 shares in LTRN as of the October 30, 2026 settlement, a 137.9% increase from the prior period — about 2.7 days to cover at its recent average daily volume. On November 20, 2026, 70.1% of LTRN volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for LTRN, detected from its recent SEC filings · based on capital-structure filings through 2026-09-30.
Registration for Resale · Potential Dilution and Market Overhang
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →